drugset / Trial / NCT01408316

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

NCT01408316

Phase 1 Completed 39 enrolled Cascadian Therapeutics Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This is a two part study designed to evaluate the PK profile of PX-866 capsules versus tablets, and to evaluate the effect of food on the PK of PX-866 tablets only in healthy volunteers.

Timeline

Start
2011-07
Primary completion
2011-10
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SONOLISIB Small molecule 6 mg
Subject SONOLISIB Small molecule 8 mg

Indications

No indication recorded.